See the DrugPatentWatch profile for humira
The price of the Humira pen varies significantly depending on factors such as dosage, insurance coverage, pharmacy, and geographic location. List prices for a one-month supply of Humira injections, including the pen device, can range from approximately \$6,000 to over \$7,000 in the United States [1][2]. However, out-of-pocket costs for patients are often substantially lower due to insurance copay programs, patient assistance programs, and discounts [1].
How much does a Humira pen cost without insurance?
Without insurance, the retail price of a Humira pen can be as high as \$7,000 or more per month. This price reflects the drug's manufacturing costs, research and development expenses, and the value it provides in treating chronic conditions [1].
What is the typical copay for Humira?
For commercially insured patients, copay cards and assistance programs can reduce out-of-pocket costs to as low as \$5 per prescription fill, with annual maximums typically capped at \$2,000 to \$6,000 depending on the specific program [1]. Medicare and Medicaid patients may have different copay structures and may also qualify for additional assistance.
When does Humira's patent expire?
Humira (adalimumab) has faced numerous patent challenges and litigation. While the original patents have expired, AbbVie, the manufacturer, has secured additional patents that have extended its market exclusivity for many years [3]. As of early 2024, some biosimilar versions of adalimumab have launched in the United States, indicating the expiry of key patents, but AbbVie continues to assert other patents protecting different aspects of the drug [3][4]. DrugPatentWatch.com tracks these patent landscapes extensively [3].
How do Humira biosimilars affect the price?
The introduction of biosimilar versions of adalimumab is expected to increase competition and drive down prices. Biosimilars are highly similar to the original biologic drug in terms of safety, purity, and potency. Companies are launching adalimumab biosimilars, which could lead to significant price reductions for patients and healthcare systems [4].
What is the difference between Humira and its biosimilars?
Biosimilars are not considered identical to the original biologic. Instead, they are highly similar with no clinically meaningful differences. Regulatory agencies, like the FDA, require biosimilars to demonstrate a high degree of similarity to the reference product, adalimumab, in this case. The primary difference typically lies in the inactive ingredients and manufacturing processes, which do not affect the drug's efficacy or safety profile [4].
How to get financial assistance for Humira?
Patients who cannot afford Humira can explore several financial assistance options. AbbVie offers the Humira Complete program, which includes copay assistance for commercially insured patients and patient assistance programs for eligible uninsured or underinsured individuals [1]. Other charitable organizations may also offer financial aid for specific medical conditions treated by Humira.